Tennøe, Anders H.
Murbræch, Klaus
Didriksen, Henriette
Ueland, Thor
Palchevskiy, Vyacheslav
Weigt, Stephen S.
Fretheim, Håvard
Midtvedt, Øyvind
Garen, Torhild
Brunborg, Cathrine
Aukrust, Pål
Molberg, Øyvind
Belperio, John A.
Hoffmann-Vold, Anna-Maria
Funding for this research was provided by:
EkstraStiftelsen Helse og Rehabilitering
South-Eastern Norway Regional Health Authority
Norwegian Women’s Public Health Association
National Institutes of Health, Bethesda (Grant P01-HL108793)
Article History
Received: 4 December 2021
Accepted: 7 March 2022
First Online: 18 March 2022
Competing interests
: A.H. Tennøe has received consulting fees or other remuneration from GSK and Actelion. H.F. has received consulting fees or other remuneration from GSK and Actelion. H.D. has received consulting fees or other remuneration from GSK and Actelion. J.A.B. has received research funding and/or consulting fees or other remuneration from Boehringer Ingelheim and Genentech. A.M.H.-V. has received research funding and/or consulting fees and/or other remuneration from Actelion, Boehringer Ingelheim, Roche, Janssen, Bayer, Merck Sharp & Dohme, ARXX, Lilly, Medscape. The authors declare that they have no other competing interests.